Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
UNIVERSITE D'EVRY VAL D'ESSONNE currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is distributed across 1 distinct examiner and 1 distinct art unit, indicating a concentrated prosecution focus for the portfolio. The busiest examiner for the company is VIVLEMORE, TRACY ANN, who is responsible for 1 pending office action.
This concentration means that the company's immediate patent outcomes in this sector depend on the evaluations of a single individual. Practitioners should monitor the specific tendencies of this examiner within the designated art unit to anticipate potential hurdles. The presence of only 1 distinct art unit suggests that the company's current intellectual property efforts are not yet diversified across different technical classifications. This narrow focus allows for a specific legal strategy tailored to the assigned examiner's historical preferences. By focusing on the procedural history of the active examiner, the company can better prepare for the specific types of rejections or requirements that are common in this particular area of Biotechnology & Pharmaceuticals.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §102 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOESEN, CHRISTIAN C | 1 | 75.9% | +21.1% |
| CONNORS, ALEXANDRA F | 1 | 23.9% | +45.4% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
| KOROTCHKINA, LIOUBOV G | 1 | 29.5% | +67.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17625440 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | KOROTCHKINA, LIOUBOV G | 92d overdue |
| 18009006 | Treatment of Genetic Dilated Cardiomyopathies | CONNORS, ALEXANDRA F | 30d overdue |
| 17905290 | PROCESS FOR OBTAINING A PRE-VASCULARIZED DERMAL-EPIDERMAL TISSUE | SCHUBERG, LAURA J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17625440 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | KOROTCHKINA, LIOUBOV G | 92d overdue |
| 18009006 | Treatment of Genetic Dilated Cardiomyopathies | CONNORS, ALEXANDRA F | 30d overdue |
| 18013339 | Method for Engineering Novel Hybrid AAV Capsids Through Hyper Variable Regions Swapping | BOESEN, CHRISTIAN C | — |
| 17905290 | PROCESS FOR OBTAINING A PRE-VASCULARIZED DERMAL-EPIDERMAL TISSUE | SCHUBERG, LAURA J | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| 1634 | 1 |
| 1631 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18013339 | Method for Engineering Novel Hybrid AAV Capsids Through Hyper Variable Regions Swapping | BOESEN, CHRISTIAN C | 1684 | §102 | Non-Final OA | — | Pending | Dec 28, 2022 |
| 18009006 | Treatment of Genetic Dilated Cardiomyopathies | CONNORS, ALEXANDRA F | 1634 | §103§112 | Final Rejection | 30d overdue | Pending | Dec 08, 2022 |
| 17905290 | PROCESS FOR OBTAINING A PRE-VASCULARIZED DERMAL-EPIDERMAL TISSUE | SCHUBERG, LAURA J | 1631 | §103 | Final Rejection | — | Pending | Aug 30, 2022 |
| 17625440 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | KOROTCHKINA, LIOUBOV G | 1653 | §103 | Final Rejection | 92d overdue | Pending | Jan 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial